Alvimopan monohydrate

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

一种选择性外周作用 μ-阿片类拮抗剂，IC50 为 1.7 nM，用于治疗术后肠梗阻。

A selective peripherally acting μ-opioid antagonist with IC50 of 1.7 nM for the treatment of postoperative ileus; prevents gastrointestinal effects of intravenous morphine without affecting analgesia; orally active.Other Indication Approved.

Alvimopan inhibits the loperamide-stimulated [35S]GTPγS binding to membranes containing the cloned human μ-opioid receptor, with an IC50 of 1.7 nM.

Alvimopan (0.1-1.0 mg/kg; p.o.) partially antagonizes the slowing of small intestinal transit of 113Sn-labelled microspheres in rats.Alvimopan (3 mg/kg; p.o.) has no effect on the visceromotor behavioural responses (VMR) induced by noxious colorectal distension (CRD) in conscious rats.

Alvimopan monohydrate

Endocrinology/Hormones

Opioid Receptor

Opioid Receptor

Other Indications

Other Disease

1383577-62-5

442.5479

C25H34N2O5

>98% (HPLC)

10 mM in DMSO

C[C@H]1CN(C[C@@H](C(NCC(O)=O)=O)Cc2ccccc2)CC[C@]1(c3cc(O)ccc3)C.O

Glycine, N-[(2S)-2-[[(3R,4R)-4-(3-hydroxyphenyl)-3,4-dimethyl-1-piperidinyl]methyl]-1-oxo-3-phenylpropyl]-, hydrate (1:1)

(-20℃)

With Ice Pack

≥ 2 years